What Happened to the Plans for a Smart Contact Lens for Diabetics?
Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose…
Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose…
Genmab's leukemia drug will be available around the world through compassionate use programs, while it will…
Now that we've got the bad news out of the way, we're here to spread…
The FDA has approved Novartis' CAR-T therapy Kymriah, opening the way for a new generation…
European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’…
Editor's Note: Novartis did note a death from cerebral hemorrhage in its hearing with the…
Novartis just announced that its anti-inflammatory drug, canakinumab, was able to clear a 10,000-plus patient Phase III…
Bayer's and Regeneron's blockbuster Eylea could be facing serious competition, as Novartis boasts with positive…
Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants…
The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and…
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T…
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…